Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Phase of Trial: Phase I/II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Talazoparib (Primary)
- Indications Advanced breast cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Uterine cancer
- Focus Pharmacodynamics
- 08 May 2019 Planned End Date changed from 6 Aug 2019 to 6 Aug 2020.
- 08 May 2019 Planned primary completion date changed from 6 Aug 2019 to 6 Aug 2020.
- 31 Aug 2018 Biomarkers information updated